Mercer Global Advisors’s Damora Therapeutics, Inc. Ordinary Shares DMRA Stock Holding History

Mercer Global Advisors’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.03K	Buy	+78	New	+$1.89K	﹤0.01%	5588

Other funds holding DMRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCP

Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Mercer Global Advisors's DMRA Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Damora Therapeutics, Inc. Ordinary Shares (DMRA) in Q2 2026: 78 shares worth $2.03K. The stake represents ﹤0.01% of the portfolio and ranks #5588 among its holdings.

50 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

Mercer Global Advisors held 78 shares of Damora Therapeutics, Inc. Ordinary Shares worth $2.03K as of Q2 2026.
Damora Therapeutics, Inc. Ordinary Shares was a new Mercer Global Advisors position in Q2 2026.
Damora Therapeutics, Inc. Ordinary Shares made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #5588 holding.
50 funds tracked by Wall St. Rank held Damora Therapeutics, Inc. Ordinary Shares as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.